ESMO Consensus Conference: Pathology and molecular biomarkers for non-small-cell lung cancer

Published in 2014 - Ann Oncol (2014) 25 (9): 1681-1690. doi: 10.1093/annonc/mdu145
Authors: K.M. Kerr, L. Bubendorf, M.J. Edelman, A. Marchetti, T. Mok, S. Novello, K. O'Byrne, R. Stahel, S. Peters, E. Felip

This report from the 2nd ESMO Consensus Conference on Lung Cancer complements existing guidelines and provides recommendations by international experts on guidance on tissue handling, small biopsy/cytology diagnostic setting, testing for EGFR somatic mutations & ALK rearrangements, when to consider KRAS, BRAF, HER2, ROS1 fusion, RET fusion testing, if there is a role for ERCC1, RRM1, TS testing, the role of emerging technologies, why laboratories should participate in quality assurance programmes, and reporting data from pathological, molecular & other biomarker testing.

Download the PDF from Annals of Oncology

Last update: 08 April 2014